🚨Trade Alert 🚨 BSGM

🚨Trade Alert 🚨 BSGM͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ BSGM shares have been on a 200% rampage and there are multiple “STRONG BUY” ratings currently! Greetings Investors, Not too many arenas are more exciting than the ever-changing and rapidly growing healthcare space. Whether the economy is good or bad, healthcare spending continues because people need services and medicines. U.S. healthcare spending grew 2.7 percent in 2021, reaching a massive~/AASl5QA~/RgRl10Y-P0TcaHR0cHM6Ly93d3cuY21zLmdvdi9yZXNlYXJjaC1zdGF0aXN0aWNzLWRhdGEtYW5kLXN5c3RlbXMvc3RhdGlzdGljcy10cmVuZHMtYW5kLXJlcG9ydHMvbmF0aW9uYWxoZWFsdGhleHBlbmRkYXRhL25hdGlvbmFsaGVhbHRoYWNjb3VudHNoaXN0b3JpY2FsP19reD1fLUhTcG8yeTlsRFdKZTVmSzZ4MzZmZ2xjNS10Vk1sdmZGU3VHV0NlRnFKN3lwNV9vMzd3Tm9JTXpOVDBsMkRYLlRhOXJoTFcDc3BjQgpj5T7B9GMSm422Uht0cmlzdHJhbWJhbGR3aW45MUBnbWFpbC5jb21YBAAF4bE~[$4.3 trillion](~/AASl5QA~/RgRl10Y-P0TcaHR0cHM6Ly93d3cuY21zLmdvdi9yZXNlYXJjaC1zdGF0aXN0aWNzLWRhdGEtYW5kLXN5c3RlbXMvc3RhdGlzdGljcy10cmVuZHMtYW5kLXJlcG9ydHMvbmF0aW9uYWxoZWFsdGhleHBlbmRkYXRhL25hdGlvbmFsaGVhbHRoYWNjb3VudHNoaXN0b3JpY2FsP19reD1fLUhTcG8yeTlsRFdKZTVmSzZ4MzZmZ2xjNS10Vk1sdmZGU3VHV0NlRnFKN3lwNV9vMzd3Tm9JTXpOVDBsMkRYLlRhOXJoTFcDc3BjQgpj5T7B9GMSm422Uht0cmlzdHJhbWJhbGR3aW45MUBnbWFpbC5jb21YBAAF4bE~)or $12,914 per person. If those numbers have you ready to read up on healthcare companies, there is one that should be first on the list. NASDAQ-traded BioSig Technologies, Inc. (BSGM) is currently trading at a little over $1 and may be one of the most exciting stories in healthcare going under the radar! Shares are up over 200% YTD and there could be more upside as Wall Street discovers the company. The stock currently has a “STRONG BUY” rating at both [BarChart.com](~/AASl5QA~/RgRl10Y-P0SAaHR0cHM6Ly93d3cuYmFyY2hhcnQuY29tL3N0b2Nrcy9xdW90ZXMvQlNHTS9vdmVydmlldz9fa3g9Xy1IU3BvMnk5bERXSmU1Zks2eDM2ZmdsYzUtdFZNbHZmRlN1R1dDZUZxSjd5cDVfbzM3d05vSU16TlQwbDJEWC5UYTlyaExXA3NwY0IKY-U-wfRjEpuNtlIbdHJpc3RyYW1iYWxkd2luOTFAZ21haWwuY29tWAQABeGx)~/AASl5QA~/RgRl10Y-P0SAaHR0cHM6Ly93d3cuYmFyY2hhcnQuY29tL3N0b2Nrcy9xdW90ZXMvQlNHTS9vdmVydmlldz9fa3g9Xy1IU3BvMnk5bERXSmU1Zks2eDM2ZmdsYzUtdFZNbHZmRlN1R1dDZUZxSjd5cDVfbzM3d05vSU16TlQwbDJEWC5UYTlyaExXA3NwY0IKY-U-wfRjEpuNtlIbdHJpc3RyYW1iYWxkd2luOTFAZ21haWwuY29tWAQABeGxand [Investing.com](~/AASl5QA~/RgRl10Y-P0SEaHR0cHM6Ly93d3cuaW52ZXN0aW5nLmNvbS9lcXVpdGllcy9iaW9zaWctdGVjaC10ZWNobmljYWw_X2t4PV8tSFNwbzJ5OWxEV0plNWZLNngzNmZnbGM1LXRWTWx2ZkZTdUdXQ2VGcUo3eXA1X28zN3dOb0lNek5UMGwyRFguVGE5cmhMVwNzcGNCCmPlPsH0YxKbjbZSG3RyaXN0cmFtYmFsZHdpbjkxQGdtYWlsLmNvbVgEAAXhsQ~~). Not only that, but [StockTA.com](~/AASl5QA~/RgRl10Y-P0SUaHR0cDovL3d3dy5zdG9ja3RhLmNvbS9jZ2ktYmluL2FuYWx5c2lzLnBsP3N5bWI9QlNHTSZjb2JyYW5kPSZtb2RlPXN0b2NrJl9reD1fLUhTcG8yeTlsRFdKZTVmSzZ4MzZmZ2xjNS10Vk1sdmZGU3VHV0NlRnFKN3lwNV9vMzd3Tm9JTXpOVDBsMkRYLlRhOXJoTFcDc3BjQgpj5T7B9GMSm422Uht0cmlzdHJhbWJhbGR3aW45MUBnbWFpbC5jb21YBAAF4bE~) has a “VERY BULLISH” rating while [AmericanBulls.com](~/AASl5QA~/RgRl10Y-P0SNaHR0cHM6Ly93d3cuYW1lcmljYW5idWxscy5jb20vU2lnbmFsUGFnZS5hc3B4P2xhbmc9ZW4mVGlja2VyPUJTR00mX2t4PV8tSFNwbzJ5OWxEV0plNWZLNngzNmZnbGM1LXRWTWx2ZkZTdUdXQ2VGcUo3eXA1X28zN3dOb0lNek5UMGwyRFguVGE5cmhMVwNzcGNCCmPlPsH0YxKbjbZSG3RyaXN0cmFtYmFsZHdpbjkxQGdtYWlsLmNvbVgEAAXhsQ~~) has a “Stay Long” rating. BSGM also has a high~/AASl5QA~/RgRl10Y-P4QGAWh0dHBzOi8vbW9uZXkuY25uLmNvbS9xdW90ZS9mb3JlY2FzdC9mb3JlY2FzdC5odG1sP3N5bWI9QlNHTSZfa3g9Xy1IU3BvMnk5bERXSmU1Zks2eDM2ZmdsYzUtdFZNbHZmRlN1R1dDZUZxSjd5cDVfbzM3d05vSU16TlQwbDJEWC5UYTlyaEwjOn46dGV4dD1CaW9zaWclMjBUZWNobm9sb2dpZXMlMjBJbmMlMjAoTkFTREFRJTNBQlNHTSkmdGV4dD1UaGUlMjAzJTIwYW5hbHlzdHMlMjBvZmZlcmluZyUyMDEyLHRoZSUyMGxhc3QlMjBwcmljZSUyMG9mJTIwMS4zMi5XA3NwY0IKY-U-wfRjEpuNtlIbdHJpc3RyYW1iYWxkd2luOTFAZ21haWwuY29tWAQABeGx[price target of $6](~/AASl5QA~/RgRl10Y-P4QGAWh0dHBzOi8vbW9uZXkuY25uLmNvbS9xdW90ZS9mb3JlY2FzdC9mb3JlY2FzdC5odG1sP3N5bWI9QlNHTSZfa3g9Xy1IU3BvMnk5bERXSmU1Zks2eDM2ZmdsYzUtdFZNbHZmRlN1R1dDZUZxSjd5cDVfbzM3d05vSU16TlQwbDJEWC5UYTlyaEwjOn46dGV4dD1CaW9zaWclMjBUZWNobm9sb2dpZXMlMjBJbmMlMjAoTkFTREFRJTNBQlNHTSkmdGV4dD1UaGUlMjAzJTIwYW5hbHlzdHMlMjBvZmZlcmluZyUyMDEyLHRoZSUyMGxhc3QlMjBwcmljZSUyMG9mJTIwMS4zMi5XA3NwY0IKY-U-wfRjEpuNtlIbdHJpc3RyYW1iYWxkd2luOTFAZ21haWwuY29tWAQABeGx) now, implying over another 200% in potential upside if it ever gets there. So why so many positive ratings on this company? BSGM is an advanced digital signal processing technology company delivering unprecedented accuracy and precision to intracardiac signal visualization with its proprietary PURE EP™ System. In other words, the company’s technology aims to help prevent a major health crisis, saving significant costs for both patients and the healthcare industry. To date, the Company's FDA 510(k)-cleared PURE EP™ System has been used in approximately 3,000 patient cases across the United States. And this number is growing! [The PURE EP™ System](~/AASl5QA~/RgRl10Y-P0T3aHR0cHM6Ly93d3cuZ2xvYmVuZXdzd2lyZS5jb20vVHJhY2tlcj9kYXRhPW5YdGo4Q1ZzY3JPWUVkbEh4TGd3T0pqd2ZGdThJUnQ0cjdqc01uR2o1bEk2TF9VMWNNLXVrYms1aUpMSl9BWWZkVXVFek9yd05lVzlQR0NSYVo0NEU4MFI0NG00aXlqM2RzTnFKR29ueTNQV24temNMWUJtME1tZWxXemRLR29MJl9reD1fLUhTcG8yeTlsRFdKZTVmSzZ4MzZmZ2xjNS10Vk1sdmZGU3VHV0NlRnFKN3lwNV9vMzd3Tm9JTXpOVDBsMkRYLlRhOXJoTFcDc3BjQgpj5T7B9GMSm422Uht0cmlzdHJhbWJhbGR3aW45MUBnbWFpbC5jb21YBAAF4bE~)~/AASl5QA~/RgRl10Y-P0T3aHR0cHM6Ly93d3cuZ2xvYmVuZXdzd2lyZS5jb20vVHJhY2tlcj9kYXRhPW5YdGo4Q1ZzY3JPWUVkbEh4TGd3T0pqd2ZGdThJUnQ0cjdqc01uR2o1bEk2TF9VMWNNLXVrYms1aUpMSl9BWWZkVXVFek9yd05lVzlQR0NSYVo0NEU4MFI0NG00aXlqM2RzTnFKR29ueTNQV24temNMWUJtME1tZWxXemRLR29MJl9reD1fLUhTcG8yeTlsRFdKZTVmSzZ4MzZmZ2xjNS10Vk1sdmZGU3VHV0NlRnFKN3lwNV9vMzd3Tm9JTXpOVDBsMkRYLlRhOXJoTFcDc3BjQgpj5T7B9GMSm422Uht0cmlzdHJhbWJhbGR3aW45MUBnbWFpbC5jb21YBAAF4bE~is currently in a national commercial launch and an integral part of well-respected healthcare systems, such as Mayo Clinic, Texas Cardiac Arrhythmia Institute, Cleveland Clinic, and Kansas City Heart Rhythm Institute. "If we improve the fidelity of our [signal] recordings, we can potentially improve the efficiency and safety of our procedures. In that respect, the PURE EP™ System is really a breath of fresh air in this field." - Hicham El Masry, M.D. (Mayo Clinic, Arizona) In a [blinded clinical study](~/AASl5QA~/RgRl10Y-P4S3AWh0dHBzOi8vd3d3Lmdsb2JlbmV3c3dpcmUuY29tL1RyYWNrZXI_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-U-wfRjEpuNtlIbdHJpc3RyYW1iYWxkd2luOTFAZ21haWwuY29tWAQABeGx) recently published in the Journal of Cardiovascular Electrophysiology, electrophysiologists rated PURE EP™ as equivalent or superior to conventional systems for 93.6% of signal samples, with 75.2% earning a superior rating! This bodes well for BSGM, as the global EP market is projected to reach [$16B in 2028](~/AASl5QA~/RgRl10Y-P0TMaHR0cDovL2NhcmRpYWN2YXNjdWxhcm5ld3MuY29tL2Jpb3NpZy1leGVjdXRlcy1wdXJjaGFzZS1hZ3JlZW1lbnQtd2l0aC1tZXRob2Rpc3QtaG9zcGl0YWwtc2FuLWFudG9uaW8tYW5kLWV4cGFuZHMtY3VzdG9tZXItYmFzZS8_X2t4PV8tSFNwbzJ5OWxEV0plNWZLNngzNmZnbGM1LXRWTWx2ZkZTdUdXQ2VGcUo3eXA1X28zN3dOb0lNek5UMGwyRFguVGE5cmhMVwNzcGNCCmPlPsH0YxKbjbZSG3RyaXN0cmFtYmFsZHdpbjkxQGdtYWlsLmNvbVgEAAXhsQ~~) with an 11.2% growth rate. The system was also highlighted in a peer-reviewed case report by the [Journal of Atrial Fibrillation & Electrophysiology (JAFIB-EP)](~/AASl5QA~/RgRl10Y-P4QlAmh0dHBzOi8vd3d3Lmdsb2JlbmV3c3dpcmUuY29tL1RyYWNrZXI_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~). This clinical abstract detailed the value of PURE EP™ and its groundbreaking High Frequency Algorithm (HFA) during pulmonary vein isolation. It may be just a matter of time before more of Wall Street recognizes the company and its PURE EP System. BSGM is poised to be an emerging leader based on the exciting commercial, technology and corporate activities that are underway this year. Now may be the best time to have the stock on your radar! [](~/AASl5QA~/RgRl10Y-P0RjaHR0cHM6Ly93d3cuYmlvc2lnLmNvbS8_X2t4PV8tSFNwbzJ5OWxEV0plNWZLNngzNmZnbGM1LXRWTWx2ZkZTdUdXQ2VGcUo3eXA1X28zN3dOb0lNek5UMGwyRFguVGE5cmhMVwNzcGNCCmPlPsH0YxKbjbZSG3RyaXN0cmFtYmFsZHdpbjkxQGdtYWlsLmNvbVgEAAXhsQ~~) BioSig Technologies, Inc. NASDAQ: BSGM BioSig Technologies is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals. Many investors are on a quest to find companies that are focused on the biggest trends in healthcare and exhibit major growth potential. This includes the bioelectronic medicine space, which is a rapidly growing segment of healthcare that explores how targeted electrical signals can harness the body’s natural mechanisms to diagnose and treat a range of diseases. The company offers an unmatched perspective in bioelectronic medicine that ensures anything of potential significance never gets overlooked. The space, which includes familiar devices such as pacemakers, is expected to [exceed a staggering $60 billion market by 2029!](~/AASl5QA~/RgRl10Y-P0ScaHR0cHM6Ly93d3cuaWR0ZWNoZXguY29tL2VuL3Jlc2VhcmNoLXJlcG9ydC9iaW9lbGVjdHJvbmljLW1lZGljaW5lLTIwMTktMjAyOS82NDM_X2t4PV8tSFNwbzJ5OWxEV0plNWZLNngzNmZnbGM1LXRWTWx2ZkZTdUdXQ2VGcUo3eXA1X28zN3dOb0lNek5UMGwyRFguVGE5cmhMVwNzcGNCCmPlPsH0YxKbjbZSG3RyaXN0cmFtYmFsZHdpbjkxQGdtYWlsLmNvbVgEAAXhsQ~~) BSGM is targeting the [anticipated $15.7B electrophysiology (EP) market](~/AASl5QA~/RgRl10Y-P0TjaHR0cHM6Ly93d3cuZ2xvYmVuZXdzd2lyZS5jb20vZW4vbmV3cy1yZWxlYXNlLzIwMjIvMDcvMDUvMjQ3NDEyOS8wL2VuL0VsZWN0cm9waHlzaW9sb2d5LU1hcmtldC1hLTE1LTctYmlsbGlvbi1JbmR1c3RyeS1ieS0yMDMwLXdpdGgtYS1DQUdSLW9mLTEwLTguaHRtbD9fa3g9Xy1IU3BvMnk5bERXSmU1Zks2eDM2ZmdsYzUtdFZNbHZmRlN1R1dDZUZxSjd5cDVfbzM3d05vSU16TlQwbDJEWC5UYTlyaExXA3NwY0IKY-U-wfRjEpuNtlIbdHJpc3RyYW1iYWxkd2luOTFAZ21haWwuY29tWAQABeGx) and is seeking to serve a vital market with a device that could be a game changer. The company is on a solid path to commercial growth and orders are coming in as the company publishes impressive clinical results, expands its product pipeline, and grows internationally. More on the PURE EP™ System The PURE EP system is BSGM’s first product and is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording, and storing electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory. The patented PURE EP™ System can record raw (unaltered) cardiac and other physiologic signals with multiple display options, low noise, and a large input signal dynamic range. This is achieved using a low-noise amplifier topology with minimal filtering to band-limit the signal and a high-resolution A/D converter. In addition, the PURE EP™ System can provide large-signal (e.g., from a defibrillator) input protection and radio frequency (RF) signal (e.g., from ablation) noise suppression. There is no need for gain switching in this architecture, and the full range of input signals is digitized with high resolution. The US Patent Office had allowed a~/AASl5QA~/RgRl10Y-P0SZaHR0cHM6Ly9maW5hbmNlLnlhaG9vLmNvbS9uZXdzL2Jpb3NpZy1hd2FyZGVkLXVzLXBhdGVudC1jbGFpbXMtMTgwMDAwMzgzLmh0bWw_X2t4PV8tSFNwbzJ5OWxEV0plNWZLNngzNmZnbGM1LXRWTWx2ZkZTdUdXQ2VGcUo3eXA1X28zN3dOb0lNek5UMGwyRFguVGE5cmhMVwNzcGNCCmPlPsH0YxKbjbZSG3RyaXN0cmFtYmFsZHdpbjkxQGdtYWlsLmNvbVgEAAXhsQ~~[utility patent covering its PURE EP™ noise-filtering technology.](~/AASl5QA~/RgRl10Y-P0SZaHR0cHM6Ly9maW5hbmNlLnlhaG9vLmNvbS9uZXdzL2Jpb3NpZy1hd2FyZGVkLXVzLXBhdGVudC1jbGFpbXMtMTgwMDAwMzgzLmh0bWw_X2t4PV8tSFNwbzJ5OWxEV0plNWZLNngzNmZnbGM1LXRWTWx2ZkZTdUdXQ2VGcUo3eXA1X28zN3dOb0lNek5UMGwyRFguVGE5cmhMVwNzcGNCCmPlPsH0YxKbjbZSG3RyaXN0cmFtYmFsZHdpbjkxQGdtYWlsLmNvbVgEAAXhsQ~~) The recently allowed patent application number 17/091,357 entitled “Universal Notch Filter" was filed on November 6, 2020. The patent describes and claims computer-implemented methods for filtering noise from an input signal. “We believe we have the leading patent-protected solution for providing superior intracardiac signal information to electrophysiologists during catheter ablation procedures across all types of cardiac arrhythmias.” - Kenneth L. Londoner, Chairman, and CEO More Applications BSGM is also working with leading experts and organizations to develop additional features of PURE EP™ and explore signal processing applications in disease areas beyond arrhythmia. In 2017, the company signed a 10-year strategic collaboration with experts at the world renown Mayo Clinic to jointly develop their signal processing technology. These experts see the potential for BSGM's technology to help them electrically map the entire body, possibly leading to diagnosis and development of new therapies in other disease areas – for example, neurology and ophthalmology. New Patent Claims BSGM kicked off this year being awarded patent claims from the United States for its universal notch filter technology! Patent No. 11,569,853 was issued on January 31, 2023 and is entitled “Universal Notch Filter.” The patent describes and claims systems, methods, and computer program product embodiments of the company’s PURE EP™ System for removing any fixed frequency interfering signal from an input signal without introducing artifacts that are not part of the original signal of interest. This now makes 56 worldwide fundamental patents granted/allowed, 11 pending U.S. patent applications, and seven European/PCT applications covering its advanced signal processing technology. BSGM also has 13 pending patent applications in Asia including China, Korea, Japan and Taiwan. Achievements BSGM has built a robust pipeline of commercial sale prospects and expects multiple closings in the first half of 2023. If that isn’t exciting enough, there is new supporting clinical data to be published… so keep an eye out for this. It was only last month that marked the one-year anniversary of redefining BSGM’s product development and commercial strategies led by John Sieckhaus and Gray Fleming, respectively. In the last year the company has built new sales and clinical teams, introduced new corporate and product branding, launched potentially game-changing software, secured numerous evaluations, established new research protocols, signed purchase agreements, and created a promising revenue pipeline. A New Esteemed CFO Steve Buhaly is BSGM’s new CFO and brings over 15 years of CFO experience at three public U.S. companies to his new role with BioSig. Buhaly is a long-tenured finance and technology executive who joined Qorvo (formerly TriQuint Semiconductor) as CFO in 2007, near the time when Apple began utilizing TriQuint chips in the iPhone. TriQuint became Qorvo in 2015 in a $4 billion combination with RF Micro Devices. During Mr. Buhaly’s tenure, Qorvo grew into an $11 billion market capitalization company and a world leader in innovative and high-performance radiofrequency (RF) solutions! In Summary…. BSGM is on a mission to end reliance on mixed signals and reading between the lines. The company understands that greater clarity breeds opportunity for a new standard in cardiac care. The company brings to the world an innovation in one of the most CRITICAL areas of electrophysiology. Healthcare is one of the largest and most complex sectors and it has had investors’ attention for years. There’s a good reason why this year many blue-chip healthcare stocks have been solid gainers in a bear market on both the NASDAQ and the S&P 500 exchanges in 2022. BSGM is in commercialization right now and orders are piling up! There’s a 10-year strategic agreement with the world-famous Mayo Clinic and other big developments! If everything already mentioned hasn’t intrigued you enough, here are more headwinds to consider. These are the headwinds that are catalysts to propelling medical device stocks to the moon. Over 79 million baby boomers are getting older and living longer, and that means they require more services such as treatments for ailing hearts, along with the other privileges of aging. In addition, cardiac care is becoming a key strategic area of interest for mergers and acquisitions. With BULLISH ratings piling up, BSGM’s solution is equivalent if not superior to conventional systems and has the potential to diagnose and treat MANY diseases! This could be the beginning of a remarkable future ahead for a company! Start your research right away! Copyright 2022 © SCDalerts.com is owned and operated by the owner of SCD Media LLC. Disclaimer and Privacy For more Information please contact info@smallcapsdaily.com This website provides information about the stock market and other investments. This website does not provide investment advice and should not be used as a replacement for investment advice from a qualified professional. This website is for informational purposes only. The Author of this website is not a registered investment advisor and does not offer investment advice. You, the reader, bear responsibility for your own investment decisions and should seek the advice of a qualified securities professional before making any investment. Nothing on this website should be considered personalized financial advice. Any investments recommended here in should be made only after consulting with your personal investment advisor and only after performing your own research and due diligence, including reviewing the prospectus or financial statements of the issuer of any security. SCD Media, its managers, its employees, affiliates, and assigns (collectively "The Company") do not make any guarantee or warranty about the advice provided on this website or what is otherwise advertised above. To the maximum extent permitted by law, the Company disclaims all liability in the event any information, commentary, analysis, opinions, advice and/or recommendations provided herein prove to be inaccurate, incomplete, or unreliable, or result in any investment or other losses. You received this message as part of your subscription to SCD Alerts. SCD Alerts is a free financial news and information website. We do not directly sell any products or offer any personal financial advice, nor do we advocate the purchase or sale of any security or investment for any specific individual. We also do not make any guarantee or warranty about what is advertised above. If you have questions or concerns about a product you’ve seen in one of our emails, we encourage you to reach out to that company directly. Disclaimer – Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated, and edited by SCD Media. Any wording found in this e-mail or disclaimer referencing “I” or “we” or “our” or “SCD” refers to SCD Media. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature and are therefore unqualified to give investment recommendations. Companies with low prices per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service, you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website. We do not advise any reader to take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and its owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares, we will list the information relevant to the stock and the number of shares here. We do not own any shares in BSMG. We have been currently compensated up to Twenty Five Thousand Dollars Cash ($25,000) via bank wire transfer from a third-party Legends Media, LLC for a 1 Day Marketing Program regarding BSMG with a start date of 2/21/2023. SCD’s business model is to receive financial compensation to promote public companies. This compensation is a major conflict of interest in our ability to be unbiased regarding our alerts. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non- compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, SCD often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice. No longer want to receive these emails? [Unsubscribe](~/AASl5QA~/RgRl10Y-P0SoaHR0cHM6Ly9tYW5hZ2Uua21haWwtbGlzdHMuY29tL3N1YnNjcmlwdGlvbnMvdW5zdWJzY3JpYmU_YT1UYTlyaEwmYz0wMUdBUDRURlJIV05UMlhKRVhIREtSVjZDUCZrPWU0MzNmODEzZWUwMzhiNGJiM2Y1MTIxZTAwYzU3M2UwJm09MDFHU1FaTVY0MTNGNFEzRUdTWEhKSDFGTjAmcj1XZWNtSmg5VwNzcGNCCmPlPsH0YxKbjbZSG3RyaXN0cmFtYmFsZHdpbjkxQGdtYWlsLmNvbVgEAAXhsQ~~). Small Caps Daily 1334 Northampton St Easton, PA 18042